Factors Determining Pulmonary Deposition of Aerosolized Pentamidine in Patients with Human Immunodeficiency Virus Infection
Authors:
- Jack FuhrerJFJack Fuhrer
- Roy T. SteigbigelRSRoy T. Steigbigel
- Michael McPeckMMMichael McPeck
- 1 April 1991
- journal article
- Published by Oxford University Press (OUP) in American Review of Respiratory Disease
- Vol. 143 (4_Part_1) , 727-737
Abstract
Although aerosolized pentamidine (AP) has recently been approved for prophylaxis and is undergoing clinical trials for treatment of pneumocystis, pneumonia (PCP), factors important in the deposition of AP have not been described. Using radioaerosol techniques, deposition was measured in 22 patients receiving AP for prophylaxis or treatment of PCP. In all patients total and regional deposition of pentamidine, breathing pattern, pulmonary function (PFT), regional ventilation, and type of nebulizer were analyzed. Bronchoalveolar lavage (BAL) was performed 24 h after inhalation to assess the relationship between pentamidine levels in BAL fluid and measured aerosol deposition. The nebulizers tested were the Marquest Respirgard® II and the Cadema AeroTech® II, both previously characterized in our laboratory. The aerosol particles consist of water droplets containing dissolved pentamidine and technetium 99m bound to albumin. Analysis of particles sampled during inhalation via cascade impaction confirmed a close relationship between radioactivity in the droplets and the concentration of pentamidine as measured by HPLC (r = 0.971, p < 0.0001; n = 18). Deposition was measured by capturing inhaled and exhaled particles on absolute filters and measuring radioactivity. This technique allows the determination of the deposition fraction (DF, the fraction of the amount inhaled that is deposited), which provides information on factors strictly related to the patient. To confirm the filter measurements, pentamidine deposition was also measured by gamma camera. The camera measurement was possible because each patient's thoracic attenuation of radioactivity was determined by a quantitative perfusion scan (mg pentamidine deposited via both techniques, r = 0.949, p < 0.0001; n = 26). Regional lung volume and ventilation were determined by xenon 133 equilibrium scan and washout. Pentamidine deposition varied markedly between patients, but BAL levels of pentamidine significantly correlated with measured deposition (r = 0.819, p < 0.01; n = 9). DF averaged 0.621 ± 0.027 (SEM) and did not correlate with any measured lung parameter, including breathing pattern and PFT. Regional deposition did not correlate with regional ventilation. The major factor influencing pentamidine deposition was aerosol delivery (mg deposited versus mg inhaled; r = 0.963, p < 0.0001; n = 26). The nebulizer was an important determinant of aerosol delivery, with the AeroTech delivering between 2.5 and 5 times more drug than the Respirgard. These observations are important in assessing treatment failure and cost of therapy.Keywords
This publication has 8 references indexed in Scilit:
- Generation and Administration of Aerosols for Medical and Physiological Research StudiesJournal of Aerosol Medicine, 1989
- Characteristics of Nebulizers Used in the Treatment of AIDS-Related Pneumocystis Carinii PneumoniaJournal of Aerosol Medicine, 1988
- Interpretation of "24 Hour Lung Retention" in Studies of Mucociliary ClearanceJournal of Aerosol Medicine, 1988
- Influence of Human Lung Morphology on Particle DepositionJournal of Aerosol Medicine, 1988
- Human variation in the peripheral air-space deposition of inhaled particlesJournal of Applied Physiology, 1987
- Output characteristics from three medical nebulizersJournal of Aerosol Science, 1986
- Flow limitation, cough, and patterns of aerosol deposition in humansJournal of Applied Physiology, 1985
- Voluntary induced alterations in regional ventilation in normal humansJournal of Applied Physiology, 1984